{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:43:24Z","timestamp":1791233004151,"version":"4.1.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Noninvasive molecular biomarkers are needed to improve the early, accurate and precise diagnosis of invasive cutaneous melanoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To independently validate a previously identified circulating microRNA signature of melanoma (MEL38), and, secondly, to develop a complementary microRNA signature, optimized for prognostication.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>MicroRNA expression profiling was performed on plasma samples from a multicentre observational case\u2013control study, involving patients with primary or metastatic melanoma, melanoma in situ, nonmelanoma skin cancer, or benign naevi. MicroRNA profiles from patients with length of survival, treatment and sentinel lymph node biopsy (SLNB) data were used to develop the prognostic signature. The primary outcome of interest for MEL38 was its association with melanoma status, including area under the curve, binary diagnostic sensitivity and specificity, and incidence-adjusted positive and negative predictive values. The prognostic signature was assessed using rates of survival per risk group and relationship to conventional predictors of outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Circulating microRNA profiles of 372 patients with invasive melanoma and 210 control individuals were generated. The average age of all participants was 59\u2005years; 49% were male. A MEL38 score &amp;gt; 5.5 indicated the presence of invasive melanoma. Overall, 551\/582 (95%) of patients were correctly diagnosed, with 93% sensitivity and 98% specificity. MEL38 score ranged from 0 to 10 with an area under the curve of 0.98 (95% confidence interval 0.97\u20130.99, P &amp;lt; 0.001). A novel prognostic 12-microRNA signature (MEL12) developed from 232 patients identified low-, standard- or high-risk groups, with 94%, 78% and 58% rates of 10-year melanoma-specific\u00a0survival, respectively (log-rank P &amp;lt; 0.001). MEL12 prognostic risk groups were significantly associated with clinical staging (\u03c72, P &amp;lt; 0.001) and SLNB status (P = 0.027). Patients who were classified as high risk by MEL12 were approximately three times more likely to have melanoma detected in their sentinel lymph nodes compared to low-risk patients.\u00a0<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The circulating MEL38 signature may assist in diagnosing patients with invasive melanoma vs. other conditions associated with a lower \u2013 or negligible \u2013 risk of mortality. A complementary and prognostic MEL12 signature is predictive of SLNB status, clinical stage and probability of survival. Plasma microRNA profiling may help to optimize existing diagnostic pathways as well as enable personalized, risk-informed melanoma treatment decisions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljad137","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T11:36:25Z","timestamp":1683286585000},"page":"292-301","source":"Crossref","is-referenced-by-count":25,"title":["Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma"],"prefix":"10.1093","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2828-4175","authenticated-orcid":false,"given":"Ryan","family":"Van Laar","sequence":"first","affiliation":[{"name":"Geneseq Biosciences , Melbourne, Victoria , Australia"},{"name":"Australian Clinical Laboratories , Clayton, Victoria , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Latif","sequence":"additional","affiliation":[{"name":"Australian Clinical Laboratories , Clayton, Victoria , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"King","sequence":"additional","affiliation":[{"name":"Australian Clinical Laboratories , Clayton, Victoria , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Love","sequence":"additional","affiliation":[{"name":"Geneseq Biosciences , Melbourne, Victoria , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Taubenheim","sequence":"additional","affiliation":[{"name":"Australian Clinical Laboratories , Clayton, Victoria , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esha","family":"Kalansooriya","sequence":"additional","affiliation":[{"name":"Australian Clinical Laboratories , Clayton, Victoria , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wandi","family":"Wang","sequence":"additional","affiliation":[{"name":"Australian Clinical Laboratories , Clayton, Victoria , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirette","family":"Saad","sequence":"additional","affiliation":[{"name":"Australian Clinical Laboratories , Clayton, Victoria , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Winship","sequence":"additional","affiliation":[{"name":"Geneseq Biosciences , Melbourne, Victoria , Australia"},{"name":"The University of Melbourne , Parkville, Victoria , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Azzi","sequence":"additional","affiliation":[{"name":"Newcastle Skin Check , New South Wales , Australia"},{"name":"School of Medicine, University of Queensland , Queensland , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alister","family":"Lilleyman","sequence":"additional","affiliation":[{"name":"Newcastle Skin Check , New South Wales , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Landgren","sequence":"additional","affiliation":[{"name":"Australian Clinical Laboratories , Clayton, Victoria , Australia"},{"name":"The University of Melbourne , Parkville, Victoria , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"2023122117351675600_ljad137-B1","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1001\/jama.2020.2669","article-title":"Melanoma diagnoses rise while mortality stays fairly flat, raising concerns about overdiagnosis","volume":"323","author":"Rubin","year":"2020","journal-title":"JAMA"},{"key":"2023122117351675600_ljad137-B2","doi-asserted-by":"crossref","first-page":"j2813","DOI":"10.1136\/bmj.j2813","article-title":"Pathologists\u2019 diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study","volume":"357","author":"Elmore","year":"2017","journal-title":"BMJ"},{"key":"2023122117351675600_ljad137-B3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/jama.2016.8465","article-title":"Screening for skin cancer: US Preventive Services Task Force recommendation statement","volume":"316","author":"US Preventive Services Task Force","year":"2016","journal-title":"JAMA"},{"key":"2023122117351675600_ljad137-B4","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/jamadermatol.2022.0253","article-title":"Five-year outcomes of a melanoma screening initiative in a large health care system","volume":"158","author":"Matsumoto","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2023122117351675600_ljad137-B5","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jaad.2019.10.023","article-title":"Cost and utilization of immunotherapy and targeted therapy for melanoma: cross-sectional analysis in the Medicare population, 2013 and 2015","volume":"82","author":"Seiger","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2023122117351675600_ljad137-B6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1056\/NEJMsb2019760","article-title":"The rapid rise in cutaneous melanoma diagnoses","volume":"384","author":"Welch","year":"2021","journal-title":"N Engl J Med"},{"key":"2023122117351675600_ljad137-B7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3390\/cancers3010126","article-title":"Decoding melanoma metastasis","volume":"3","author":"Damsky","year":"2010","journal-title":"Cancers (Basel)"},{"key":"2023122117351675600_ljad137-B8","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/ncb3399","article-title":"Melanoma miRNA trafficking controls tumour primary niche formation","volume":"18","author":"Dror","year":"2016","journal-title":"Nat Cell Biol"},{"key":"2023122117351675600_ljad137-B9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.31083\/j.fbl2709275","article-title":"Exosomal miR-22-3p from mesenchymal stem cells inhibits the epithelial\u2013mesenchymal transition (EMT) of melanoma cells by regulating LGALS1","volume":"27","author":"Chen","year":"2022","journal-title":"Front Biosci (Landmark Ed)"},{"key":"2023122117351675600_ljad137-B10","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/cancers12020464","article-title":"Melanoma-derived exosomal miR-125b-5p educates tumor associated macrophages (TAMs) by targeting lysosomal acid lipase A (LIPA)","volume":"12","author":"Gerloff","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2023122117351675600_ljad137-B11","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1158\/0008-5472.CAN-17-1318","article-title":"miR-204-5p and miR-211-5p contribute to BRAF inhibitor resistance in melanoma","volume":"78","author":"Diaz-Martinez","year":"2018","journal-title":"Cancer Res"},{"key":"2023122117351675600_ljad137-B12","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1152\/physiolgenomics.00116.2013","article-title":"miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma","volume":"45","author":"Bennett","year":"2013","journal-title":"Physiol Genomics"},{"key":"2023122117351675600_ljad137-B13","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1038\/jid.2008.452","article-title":"miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma","volume":"129","author":"Mueller","year":"2009","journal-title":"J Invest Dermatol"},{"key":"2023122117351675600_ljad137-B14","doi-asserted-by":"crossref","first-page":"9136","DOI":"10.1073\/pnas.0508889103","article-title":"microRNAs exhibit high frequency genomic alterations in human cancer","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023122117351675600_ljad137-B15","doi-asserted-by":"crossref","first-page":"e9685","DOI":"10.1371\/journal.pone.0009685","article-title":"Characterization of the melanoma miRNAome by deep sequencing","volume":"5","author":"Stark","year":"2010","journal-title":"PLOS ONE"},{"key":"2023122117351675600_ljad137-B16","doi-asserted-by":"crossref","first-page":"e46874","DOI":"10.1371\/journal.pone.0046874","article-title":"Identifying mRNA, microRNA and protein profiles of melanoma exosomes","volume":"7","author":"Xiao","year":"2012","journal-title":"PLOS ONE"},{"key":"2023122117351675600_ljad137-B17","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000452540","article-title":"Expression of microRNA-301a and its functional roles in malignant melanoma","volume":"40","author":"Cui","year":"2016","journal-title":"Cell Physiol Biochem"},{"key":"2023122117351675600_ljad137-B18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40659-020-00278-3","article-title":"MicroRNA-107 is a novel tumor suppressor targeting POU3F2 in melanoma","volume":"53","author":"Zhao","year":"2020","journal-title":"Biol Res"},{"key":"2023122117351675600_ljad137-B19","doi-asserted-by":"crossref","first-page":"873728","DOI":"10.3389\/fmed.2022.873728","article-title":"Current trends in circulating biomarkers for melanoma detection","volume":"9","author":"Huang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2023122117351675600_ljad137-B20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fcell.2020.00071","article-title":"miRNAs in the diagnosis and prognosis of skin cancer","volume":"8","author":"Neagu","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2023122117351675600_ljad137-B21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/biom8020021","article-title":"Circulating microRNA biomarkers in melanoma: tools and challenges in personalised medicine","volume":"8","author":"Mumford","year":"2018","journal-title":"Biomolecules"},{"key":"2023122117351675600_ljad137-B22","doi-asserted-by":"crossref","first-page":"12110","DOI":"10.18632\/oncotarget.3661","article-title":"Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer?","volume":"6","author":"Margue","year":"2015","journal-title":"Oncotarget"},{"key":"2023122117351675600_ljad137-B23","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ebiom.2015.05.011","article-title":"The prognostic and predictive value of melanoma-related microRNAs using tissue and serum: a microRNA expression analysis","volume":"2","author":"Stark","year":"2015","journal-title":"EBioMedicine"},{"key":"2023122117351675600_ljad137-B24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1479-5876-10-155","article-title":"Serum microRNAs as biomarkers for recurrence in melanoma","volume":"10","author":"Friedman","year":"2012","journal-title":"J Transl Med"},{"key":"2023122117351675600_ljad137-B25","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/1471-2407-10-262","article-title":"High-throughput miRNA profiling of human melanoma blood samples","volume":"10","author":"Leidinger","year":"2010","journal-title":"BMC Cancer"},{"key":"2023122117351675600_ljad137-B26","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1158\/1078-0432.CCR-09-2721","article-title":"Melanoma microRNA signature predicts post-recurrence survival","volume":"16","author":"Segura","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2023122117351675600_ljad137-B27","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/bjc.2017.477","article-title":"Development and validation of a plasma-based melanoma biomarker suitable for clinical use","volume":"118","author":"Van Laar","year":"2018","journal-title":"Br J Cancer"},{"key":"2023122117351675600_ljad137-B28","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2217\/bmm-2021-0289","article-title":"Translation of a circulating microRNA signature of melanoma into a solid tissue assay to improve diagnostic accuracy and precision","volume":"15","author":"Van Laar","year":"2021","journal-title":"Biomark Med"},{"key":"2023122117351675600_ljad137-B29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/CMR.0000000000000492","article-title":"A plasma microRNA biomarker of melanoma as a personalised assessment of treatment response","volume":"29","author":"van Laar","year":"2019","journal-title":"Melanoma Res"},{"key":"2023122117351675600_ljad137-B30","doi-asserted-by":"crossref","first-page":"e0211504","DOI":"10.1371\/journal.pone.0211504","article-title":"Characterisation and validation of Mel38; a multi-tissue microRNA signature of cutaneous melanoma","volume":"14","author":"Van Laar","year":"2019","journal-title":"PLOS ONE"},{"key":"2023122117351675600_ljad137-B31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jbi.2014.02.013","article-title":"Sample size estimation in diagnostic test studies of biomedical informatics","volume":"48","author":"Hajian-Tilaki","year":"2014","journal-title":"J Biomed Inform"},{"key":"2023122117351675600_ljad137-B32","volume-title":"R: a language and environment for statistical computing","author":"R Foundation","year":"2010"},{"key":"2023122117351675600_ljad137-B33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0169-2607(95)01703-8","article-title":"MedCalc: a new computer program for medical statistics","volume":"48","author":"Schoonjans","year":"1995","journal-title":"Comput Methods Programs Biomed"},{"key":"2023122117351675600_ljad137-B34","doi-asserted-by":"crossref","first-page":"E108","DOI":"10.1371\/journal.pbio.0020108","article-title":"Semi-supervised methods to predict patient survival from gene expression data","volume":"2","author":"Bair","year":"2004","journal-title":"PLoS Biol"},{"key":"2023122117351675600_ljad137-B35","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1073\/pnas.082099299","article-title":"Diagnosis of multiple cancer types by shrunken centroids of gene expression","volume":"99","author":"Tibshirani","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023122117351675600_ljad137-B36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"2023122117351675600_ljad137-B37","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jid.2019.08.002","article-title":"The evolution of \u00admelanoma\u00a0\u2013 moving beyond binary models of genetic progression","volume":"140","author":"Zeng","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2023122117351675600_ljad137-B38","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21576-8","article-title":"Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling","volume":"12","author":"Vergara","year":"2021","journal-title":"Nat Commun"},{"key":"2023122117351675600_ljad137-B39","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.clindermatol.2008.09.014","article-title":"Melanoma of the feet: misdiagnosed and misunderstood","volume":"27","author":"Albreski","year":"2009","journal-title":"Clin Dermatol"},{"key":"2023122117351675600_ljad137-B40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12943-018-0757-5","article-title":"Liquid biomarkers in melanoma: detection and discovery","volume":"17","author":"Lim","year":"2018","journal-title":"Mol Cancer"},{"key":"2023122117351675600_ljad137-B41","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41416-020-0750-9","article-title":"Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells","volume":"122","author":"Aya-Bonilla","year":"2020","journal-title":"Br J Cancer"},{"key":"2023122117351675600_ljad137-B42","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","article-title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"Liu","year":"2020","journal-title":"Ann Oncol"},{"key":"2023122117351675600_ljad137-B43","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","article-title":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set","volume":"32","author":"Klein","year":"2021","journal-title":"Ann Oncol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad137\/50873379\/ljad137.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/3\/292\/54726549\/ljad137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/3\/292\/54726549\/ljad137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T19:16:13Z","timestamp":1703186173000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/189\/3\/292\/7152924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,5,5]]},"published-print":{"date-parts":[[2023,8,24]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad137","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,5,5]]}}}